Stifel lowered the firm’s price target on Black Diamond Therapeutics (BDTX) to $15 from $16 and keeps a Buy rating on the shares. The firm updated its model for the quarter, including the cash guidance, and made adjustments to near- to mid-term expense assumptions and the commercialization timeline given the prioritization of the first-line opportunity, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDTX: